B-cells and their targeting in rheumatoid arthritis - Current concepts and future perspectives

Autoimmunity Reviews

Volumn 11, Issue 1, 2011, Pages 28-34

  Nakken, Britt ^a   Munthe, Ludvig A ^a   Konttinen, Yrjö T ^b,c,d   Sandberg, Anna Klokk ^a   Szekanecz, Zoltan ^e   Alex, Philip ^f   Szodoray, Peter ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^d COXA Hospital for Joint Replacement ^*  (Finland)

^e UNIVERSITY OF DEBRECEN   (Hungary)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cell targeting; Humoral autoimmune responses; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; ATACICEPT; B LYMPHOCYTE RECEPTOR; BELIMUMAB; BORTEZOMIB; CARFILZOMIB; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CHEMOKINE; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CYTOKINE; EPRATUZUMAB; FOSTAMATINIB; INDUCIBLE CO STIMULATOR INHIBITOR; LARGE MULTIFUNCTIONAL PROTEASOME 7 INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY CD19; OCRELIZUMAB; OFATUMUMAB; POLYCLONAL ANTIBODY; PR 957; PROTEASOME INHIBITOR; RITUXIMAB; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR 7 INHIBITOR; TOLL LIKE RECEPTOR 9 INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VELTUZUMAB;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL FUNCTION; CELL MIGRATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; GERMINAL CENTER; GLOMERULONEPHRITIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DIFFERENTIATION; MANTLE CELL LYMPHOMA; MESENCHYME CELL; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PLASMA CELL; PROGNOSIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD79; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 80855138676     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.06.010     Document Type: Review

References (67)

1. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
2. Konttinen Y.T., Bergroth V., Nordström D., Koota K., Skrifvars B., Hagman G., et al. Cellular immunohistopathology of acute, subacute and chronic synovitis in rheumatoid arthritis. Ann Rheum Dis 1985, 44:549-555.
3. Nanki T., Takada K., Komano Y., Morio T., Kanegane H., Nakajima A., et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 2009, 11:R149.
4. Takemura S., Klimiuk P.A., Braun A., Goronzy J.J., Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001, 167:4710-4718.
5. Edwards J.C., Cambridge G., Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease?. Immunology 1999, 97:188-196.
6. Roll P., Palanichamy A., Kneitz C., Dorner T., Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006, 54:2377-2386.
7. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6:823-835.
8. MacLennan I.C., Toellner K.M., Cunningham A.F., Serre K., Sze D.M., Zúñiga E., et al. Extrafollicular antibody responses. Immunol Rev 2003, 194:8-18.
9. Eckl-Dorna J., Batista F.D. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood 2009, 113:3969-3977.
10. Sweet R.A., Ols M.L., Cullen J.L., Milam A.V., Yagita H., Shlomchik M.J. Facultative role for T cells in extrafollicular toll-like receptor-dependent autoreactive B-cell responses in vivo. Proc Natl Acad Sci USA 2011, 108:7932-7937.
11. Becker H., Weber C., Storch S., Federlin K. Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity. Clin Immunol Immunopathol 1990, 56:219-225.
12. Zhang Z., Bridges S.L. Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am 2001, 27:335-353.
13. Szodoray P., Alex P., Frank M.B., Turner M., Turner S., Knowlton N., et al. A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:1466-1476.
14. Konttinen Y.T., Reitamo S., Ranki A., Häyry P., Kankaanpää U., Wegelius O. Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates. Arthritis Rheum 1981, 24:71-79.
15. Shi K., Hayashida K., Kaneko M., Hashimoto J., Tomita T., Lipsky P.E., et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001, 166:650-655.
16. Weyand C.M., Goronzy J.J. Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci 2003, 987:140-149.
17. Bugatti S., Codullo V., Caporali R., Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 2007, 6:482-487.
18. Li T.F., Mandelin J., Hukkanen M., Lassus J., Sandelin J., Santavirta S., et al. Dendritic cells in rheumatoid synovial membrane after total removal of the hyaline articular cartilage. Rheumatology 2002, 41:319-323.
19. Souto-Carneiro M.M., Burkhardt H., Müller E.C., Hermann R., Otto A., Kraetsch H.G., et al. Human monoclonal rheumatoid synovial B lymphocyte hybridoma with a new disease-related specificity for cartilage oligomeric matrix protein. J Immunol 2001, 166:4202-4208.
20. Szodoray P., Szabó Z., Kapitány A., Gyetvai A., Lakos G., Szántó S., et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010, 9:140-143.
21. Rantapää-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
22. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
23. Puppo F., Murdaca G., Ghio M., Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005, 8:537-541.
24. Szodoray P., Alex P., Dandapani V., Nakken B., Pesina J., Kim X., et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol 2004, 60:209-218.
25. Goldenberg D.M., Morschhauser F., Wegener W.A. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010, 51:747-755.
26. Hutas G. Ocrelizumab a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs 2008, 9:1206-1215.
27. Castillo J., Milani C., Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 2009, 18:491-500.
28. Tedder T.F., Poe J.C., Haas K.M. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005, 88:1-50.
29. Carnahan J., Wang P., Kendall R., Chen C., Hu S., Boone T., et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003, 9:3982S-3990S.
30. Le Pottier L., Devauchelle V., Pers J.O., Jamin C., Youinou P. The mosaic of B-cell subsets (with special emphasis on primary Sjögren's syndrome). Autoimmun Rev 2007, 6:149-154.
31. Benucci M., Manfredi M., Puttini P.S., Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?. Autoimmun Rev 2010, 9:801-803.
32. Dörner T., Kinnman N., Tak P.P. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010, 125:464-475.
33. Stolz C., Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 2009, 50:873-885.
34. Muhammad K., Roll P., Einsele H., Dörner T., Tony H.P. Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. Arthritis Rheum 2009, 60:2284-2293.
35. Senolt L., Vencovský J., Pavelka K., Ospelt C., Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009, 9:102-107.
36. Awan F.T., Lapalombella R., Trotta R., Butchar J.P., Yu B., Benson D.M., et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010, 115:1204-1213.
37. Scheel T., Gursche A., Zacher J., Häupl T., Berek C. V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis. Arthritis Rheum 2011, 63:63-72.
38. Park Y.W., Pryshchep S., Seyler T.M., Goronzy J.J., Weyand C.M. B cells as a therapeutic target in autoimmune diseases. Expert Opin Ther Targets 2005, 9:431-445.
39. Hoyer B.F., Mumtaz I.M., Yoshida T., Hiepe F., Radbruch A. How to cope with pathogenic long-lived plasma cells in autoimmune diseases. Ann Rheum Dis 2008, 67(Suppl 3):iii87-iii89.
40. Fisher R.I., Bernstein S.H., Kahl B.S., Djulbegovic B., Robertson M.J., de Vos S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
41. van der Heijden J.W., Oerlemans R., Lems W.F., Scheper R.J., Dijkmans B.A., Jansen G. The proteasome inhibitor bortezomib inhibits the release of NFκB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 2009, 27:92-98.
42. Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755.
43. Yannaki E., Papadopoulou A., Athanasiou E., Kaloyannidis P., Paraskeva A., Bougiouklis D., et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum 2010, 62:3277-3288.
44. Muchamuel T., Basler M., Aujay M.A., Suzuki E., Kalim K.W., Lauer C., et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009, 15:781-787.
45. Kuhn J.D., Orlowski Z.R., Bjorklund C.C. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 2011, 11:285-295.
46. Rafei M., Hsieh J., Fortier S., Li M., Yuan S., Birman E., et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008, 112:4991-4998.
47. Li Y., Chen F., Putt M., Koo Y.K., Madaio M., Cambier J.C., et al. J B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. Immunol. 2008, 181:2961-2972.
48. Genovese M.C., Kavanaugh A., Weinblatt M.E., Peterfy C., DiCarlo J., White M.L., et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011, 63:337-345.
49. Weinblatt M.E., Kavanaugh A., Burgos-Vargas R., Dikranian A.H., Medrano-Ramirez G., Morales-Torres J.L., et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58:3309-3318.
50. Zheng X., Suzuki M., Zhang X., Ichim T.E., Zhu F., Ling H., et al. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther 2010, 12:R13.
51. Salzer U., Maul-Pavicic A., Cunningham-Rundles C., Urschel S., Belohradsky B.H., Litzman J., et al. ICOS deficiency in patients with common variable immunodeficiency. Clin Immunol 2004, 113:234-240.
52. Frey O., Meisel J., Hutloff A., Bonhagen K., Bruns L., Kroczek R.A., et al. Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis. Ann Rheum Dis 2010, 69:1495-1501.
53. Ganguly D., Chamilos G., Lande R., Gregorio J., Meller S., Facchinetti V., et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009, 206:1983-1994.
54. Tamaki Y., Takakubo Y., Hirayama T., Konttinen Y.T., Goodman S.B., Yamakawa M., et al. Expression of toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol 2010, 38:810-820.
55. Barrat F.J., Coffman R.L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008, 223:271-283.
56. Mackay F., Figgett W.A., Saulep D., Lepage M., Hibbs M.L. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010, 237:205-225.
57. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005, 1050:34-39.
58. Szodoray P., Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. Scand J Immunol 2005, 62:421-428.
59. Tak P.P., Thurlings R.M., Rossier C., Nestorov I., Dimic A., Mircetic V., et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008, 58:61-72.
60. Navarra S.V., Guzmán R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
61. Duty J.A., Szodoray P., Zheng N.Y., Koelsch K.A., Zhang Q., Swiatkowski M., et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009, 206:139-151.
62. Mauri C. Regulation of immunity and autoimmunity by B cells. Curr Opin Immunol 2010, 22:761-767.
63. Blair P.A., Noreña L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010, 32:129-140.
64. Visentini M., Ludovisi S., Petrarca A., Pulvirenti F., Zaramella M., Monti M., et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev May 5 2011.
65. Bosello S., De Luca G., Tolusso B., Lama G., Angelucci C., Sica G., et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2010, [Apr 22, Electronic publication ahead of print].
66. Benucci M., Manfredi M., Puttini P.S., Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?. Autoimmun Rev 2010, 9:801-803.
67. Dörner T., Isenberg D., Jayne D., Wiendl H., Zillikens D., Burmester G. International roundtable on B cells as therapeutic target for intervention. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 2009, 9:82-89.